Neumora Therapeutics, Inc.

NMRA

{{popupValue}}
{{popupSubtitle}}

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
NMRA
CIK0001885522
SIC2836
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupBiological Products, Except Diagnostic Substances

Contact

Address490 ARSENAL WAY, SUITE 200, WATERTOWN, MA, 02472
Website neumoratx.com
Phone(857) 760-0900
CEOHenry O. Gosebruch
EmployeesN/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
RevenueN/A
Pre-Tax Income$-257.78 million
Net Income$-258.06 million
Net Income to Common$-258.06 million
EPS$-1.61
View All
Balance Sheet
Cash$126.86 million
Assets$256.75 million
Liabilities$28.38 million
Common Equity$228.36 million
Liabilities & Equity$256.75 million
View All
Cash Flow Statement
Calculations
NOPAT$-192.03 million
EBITDA$-273.79 million
Price to EarningsN/A
Price to Book$0.57
ROE-79.05%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M

Over the last 7 days, the United States market has dropped 1.1%, but it is up 9.1% over the past year, with earnings forecast to grow by 14% annually. For those looking to invest in smaller or newer companies, penny stocks — despite their somewhat outdated name — can still offer surprising value when paired with solid financial foundations. This article highlights three such penny stocks that present compelling opportunities due to their financial strength and potential for growth.

Article Link

Neumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ...

Neumora Therapeutics Inc (NMRA) showcases strategic advancements and financial resilience, despite challenges in clinical trials and increased net loss.

Article Link

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025 Secured $125 million venture debt facility from K2 HealthVentures, with $40 million available in 202

Article Link

Will Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Article Link

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Monday, May 12, 2025 to report its first quarter 2025 financial results and provide a business update. A live webcast of the event will be available on the events

Article Link